Evaluation of Prostate Cancer with PET/MRI

In the ongoing effort to understand and cure prostate cancer, imaging modalities are constantly evolving to assist in clinical decisions. Multiparametric MRI can be used to direct prostate biopsies, improve diagnostic yield, and help clinicians make more accurate decisions. PET is superior in providing biologic information about the cancer and is sensitive and highly specific. Integrated PET/MRI is a welcome technical advance with great potential to influence the diagnosis and management of prostate cancer in clinical practice.

[1]  M. Schwaiger,et al.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. , 2016, European urology.

[2]  J Alfred Witjes,et al.  Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. , 2016, European urology.

[3]  Baris Turkbey,et al.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer , 2016, CA: a cancer journal for clinicians.

[4]  Kristina Schwamborn,et al.  68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[5]  P. Choyke,et al.  Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. , 2016, Urology.

[6]  J. Czernin,et al.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients , 2016, The Journal of Nuclear Medicine.

[7]  E. Kauppila,et al.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial , 2016, Acta oncologica.

[8]  Steve Y. Cho,et al.  Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[9]  Patrick Veit-Haibach,et al.  18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT , 2015, Nuclear medicine communications.

[10]  P. Choyke,et al.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. , 2015, Urologic oncology.

[11]  B. Gückel,et al.  Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here , 2015, Molecular Imaging and Biology.

[12]  Toby C. Cornish,et al.  18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[13]  Harald H Quick,et al.  Current image acquisition options in PET/MR. , 2015, Seminars in nuclear medicine.

[14]  Nikolaos Dikaios,et al.  Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images , 2015, Prostate Cancer and Prostatic Disease.

[15]  J. Bernhard,et al.  Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. , 2015, The Journal of urology.

[16]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[17]  M. Roethke,et al.  Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  P. Choyke,et al.  Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy. , 2014, The Journal of urology.

[19]  P. Choyke,et al.  Multiparametric magnetic resonance imaging and image-guided biopsy to detect seminal vesicle invasion by prostate cancer. , 2014, Journal of endourology.

[20]  G. V. von Schulthess,et al.  Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. , 2014, Radiology.

[21]  Sergios Gatidis,et al.  Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. , 2014, Radiology.

[22]  L. Ceriani,et al.  Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis , 2014, Clinical chemistry and laboratory medicine.

[23]  Sebastian Fürst,et al.  PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT , 2014, The Journal of Nuclear Medicine.

[24]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[25]  A. Afaq,et al.  Qualitative and Quantitative Comparison of PET/CT and PET/MR Imaging in Clinical Practice , 2014, The Journal of Nuclear Medicine.

[26]  Felix Nensa,et al.  Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  A. Kopp-Schneider,et al.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Andrea Soricelli,et al.  Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study. , 2013, Radiology.

[29]  C. Claussen,et al.  Seminal Vesicle Invasion: Accuracy and Analysis of Infiltration Patterns with High-Spatial Resolution T2-Weighted Sequences on Endorectal Magnetic Resonance Imaging , 2013, Urologia Internationalis.

[30]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[31]  Sibylle Ziegler,et al.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Shankar Vallabhajosula,et al.  Prostate-specific membrane antigen-based imaging. , 2013, Urologic oncology.

[33]  James Nagarajah,et al.  Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Thomas Hambrock,et al.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. , 2012, European urology.

[35]  A. Drzezga,et al.  First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.

[36]  C. Kuhl,et al.  MRI-Based Attenuation Correction for Hybrid PET/MRI Systems: A 4-Class Tissue Segmentation Technique Using a Combined Ultrashort-Echo-Time/Dixon MRI Sequence , 2012, The Journal of Nuclear Medicine.

[37]  I. Burger,et al.  PET/MR imaging of bone lesions – implications for PET quantification from imperfect attenuation correction , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  P. Choyke,et al.  11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation , 2012, The Journal of Nuclear Medicine.

[39]  P. Carroll,et al.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. , 2012, International journal of radiation oncology, biology, physics.

[40]  U. Haberkorn,et al.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[42]  F. Montorsi,et al.  PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  N. Blumstein,et al.  Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. , 2008, Radiology.

[44]  I. Tuerk,et al.  Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. , 2008, European urology.

[45]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[46]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[47]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[48]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  O. Hélénon,et al.  Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. , 2002, Radiology.